Engineering dendritic cell vaccines to improve cancer immunotherapy.
Perez CR, De Palma M. · 2019
Read Engineering dendritic cell vaccines to improve cancer immunotherapy. by Perez CR, De Palma M. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6881351.txt.
Introduction
Perez and De Palma review dendritic cell vaccines in Nature Communications. Dendritic cells collect antigens and present them to T cells, bridging the first, fast arm of immunity and the targeted one. That makes them a natural vehicle for cancer vaccines. So far, though, such vaccines have underdelivered in the clinic. The authors ask how better cell biology could fix that.
They focus on conventional type 1 dendritic cells, the subset best at priming killer T cells. New methods can now grow genuine versions of these cells at scale. Genetic reprogramming offers another route to build them. The review lays out a design blueprint for personalised vaccines built on this subset.
Catalog record
| CREATOR | Perez CR, De Palma M. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Engineering dendritic cell vaccines to improve cancer immunotherapy By Caleb R Perez, Michele De Palma Published in: Nature Communications DOI: 10.1038/s41467-019-13368-y ABSTRACT Abstract At the interface between the innate and adaptive immune system, dendritic cells (DCs) play key roles in tumour immunity and hold a hitherto unrealized potential for cancer immunotherapy. Here we review the role of distinct DC subsets in the tumour microenvironment, with special emphasis on conventional type 1 DCs. Integrating new knowledge of DC biology and advancements in cell engineering, we provide a blueprint for the rational design of optimized DC vaccines for personalized cancer medicine. Subject terms: Cancer immunotherapy, Tumour immunology INTRODUCTION Reprogramming of the immune system against cancer has shown clinical promise in recent years. Dendritic cells (DCs) are a particularly interesting immunotherapeutic target given their ability to uptake and present tumour-associated antigens (TAAs) through a variety of mechanisms (Box 1), priming potent effector responses against the tumour1–3. Besides direct antigen presentation, additional DC-intrinsic properties are relevant for immunotherapy, including the capacity to migrate between lymphoid and non-lymphoid tissues and modulate cytokine and chemokine gradients to control inflammation and lymphocyte homing, all of which are likely important for systemic and long-lasting anti-tumour effects. To leverage these features, personalized vaccines comprising patient-derived DCs manipulated ex vivo have been extensively studied. These therapies are generally manufactured by isolating monocytes or hematopoietic stem and progenitor cells (HSPCs) from peripheral blood, which are subsequently treated with recombinant cytokines to induce differentiation, stimulated to induce maturation, and loaded with TAAs of various forms, a process that has been utilized in numerous preclinical and clinical studies4. Although multiple clinical trials have demonstrated the safety and immunogenicity of DC vaccines, clinical responses have been largely disappointing. This can be attributed in part to functional deficiencies in the cells that comprise conventional vaccine formulations—such as insufficient antigen presentation, migratory capacity, and cytokine release—which poorly equip them to overcome the immunosuppressive tumour microenvironment that limits DC and effector cell function4–6. Recent studies have begun to expand our knowledge of the roles that DCs play in anti-tumour immune responses, and have revealed new methods for the generation of DC vaccines. In this Perspective, we lean on these investigations to identify types of DCs with the greatest therapeutic potential, as well as strategies to engineer them toward improved efficacy. Synthesizing this information, we aim to provide a blueprint for the design and manufacture of the next generation of personalized DC vaccines. Box 1 Mechanisms of TAA presentation by DCsCross-presentation—Presentation of internalized TAAs on endogenous MHCI, capable of inducing the activation of TAA-specific CD8+ T cells. Antigens are processed via two distinct intracellular pathways following internalization100: (i) the cytosolic pathway, in which antigens are exported to the cytosol from the endosome and processed by the proteasome into antigenic peptides that are loaded onto MHCI, and (ii) the vacuolar pathway, in which antigens are processed by lysosomal proteases and loaded onto MHCI directly in the endosome.Cross-dressing—Uptake and recycling of pre-formed peptide-MHC complexes shed by tumour cells, capable of inducing the activation of TAA-specific CD8+ T cells without the need for further processing. Transfer of peptide-MHC complexes is proposed to occur via trogocytosis101 (inter-cellular transfer of plasma membrane fragments) or transfer of EV71,102.Antigen transfer—Transfer of TAA peptides processed by exogenous cells to DCs and subsequently loaded on endogenous MHCI, capable of inducing the activation of TAA-specific CD8+ T cells. Transfer of antigenic peptides is proposed to occur through gap junctions103,104.MHCII-restricted presentation—Presentation of internalized TAAs on MHCII, capable of inducing the activation of TAA-specific CD4+ T cells105. Antigens are processed in endosomal compartments by lysosomal proteases to yield antigenic peptides, after which peptide-MHCII complexes are generated and transported to the plasma membrane for presentation. CONTRIBUTION OF DCS TO ANTI-TUMOUR IMMUNITY DCs consist of multiple distinct subsets, most commonly classified by ontogeny, including four major populations; the full DC landscape has been reviewed elsewhere1. These include plasmacytoid DCs (pDCs); conventional DCs (cDCs), which are further split into type 1 (cDC1) and type 2 (cDC2); and monocyte-derived DCs (MoDC). Each subset differs in its capacity for antigen presentation, migration, and cytokine secretion. Thus, the choice of cell type is a crucial parameter in the engineering of DC vaccines. Monocyte-derived DCs MoDCs comprise a heterogeneous population of antigen-presenting cells (APCs) that arise mainly from monocyte precursors in response to inflammation1. The majority of clinical trials utilize MoDCs generated ex vivo for operational reasons, as large populations of mature antigen-loaded MoDCs can be easily obtained from peripheral blood-derived CD14+ monocytes or CD34+ HSPCs via treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4)4,6. MoDCs generated ex vivo have been tested extensively in vaccination studies4,6,7, which demonstrated their capacity to cross-prime T cells8–10 and produce anti-tumoural cytokines, such as IL-12 (ref. 11). This has translated to anti-tumoural activity in a subset of treated patients, illustrating the potential of MoDCs as a valuable vaccine consitutent11,12. However, the magnitude of clinical response has been modest in the majority of patients, perhaps owing to incomplete recapitulation of physiological MoDC development captured by ex vivo differentiation methods. Indeed, GM-CSF and IL-4 treatment of both murine and human precursors has been shown to produce MoDCs that are transcriptionally and phenotypically distinct from their naturally occurring (primary) counterparts10,13. This distinction appears to translate to functional deficiencies in ex vivo-derived MoDCs, such as reduced T cell priming capacity relative to CD11c+ DCs isolated from peripheral blood14. In addition, MoDCs generated ex vivo may have limited migratory capacity to lymph nodes15–17, likely contributing to the suboptimal efficacy of such vaccine formulations. Conventional type 1 DCs Mounting evidence suggests that cDC1s play an integral role in tumour immunity and represent a promising alternate cell type for vaccination purposes. Bulk gene expression profiles of whole tumours indicate that cDC1 gene signatures correlate with improved prognosis across a wide range of malignancies, although inconsistency in what constitutes cDC1-specific gene signatures could confound this analysis3. Recently published single-cell RNA sequencing (scRNA-seq) analysis of non-small-cell lung cancer (NSCLC) samples, in which immune cells were grouped by unsupervised clustering without the bias of pre-selected reference genes, provided strong evidence that cDC clusters correlate with improved survival18. Numerous pre-clinical studies that used cDC1 depletion models based on mice deficient in Batf3 (also known as basic leucine zipper ATF-like transcription factor 3), a transcription factor crucial for cDC1 development19, demonstrate the requirement of cDC1s for immunogenic tumour rejection20,21, as well as for responses to immunotherapies such as immune checkpoint blockade22,23 and adoptive T cell transfer24. There appear to be multiple mechanisms by which cDC1s mediate tumour immunity, involving a range of specialized functions. Perhaps most importantly, cDC1s are known to be highly efficient in the cross-presentation on major histocompatibility class I (MHCI) molecules of exogenous antigens (Box 1) to CD8+ T cells1, a cell type strongly correlated with prognosis across various cancers25. Indeed, cross-presentation specifically by cDC1s was shown to be necessary for tumour rejection20. The BEACH domain-containing protein WDFY4 was identified by clustered regularly interspaced short palindromic repeats (CRISPR) screen to be necessary for cross-presentation in both primary splenic cDC1s and ex vivo-differentiated cDC1s, and Wdfy4–/– mice failed to mediate rejection of a highly immunogenic fibrosarcoma model. Although exact mechanisms are not yet clear, it was proposed that WDFY4